Latest: FDA Approves New Biosimilar for Oncology Treatment

FDA Accepts Type C Meeting for Doxorubicin-MNA in Basal Cell Carcinoma of the Skin

by Cancer Network

14 September, 2025

0 Mins

D-MNA achieved complete clinical clearance in 60% of patients, with no dose-limiting toxicities or serious adverse effects observed in those with basal cell carcinoma of the skin.

Tags:

Author

Cancer Network

Weighing Relapse Risk Against Benefit in Advanced NSCLC Immunotherapy: Jonathan Thompson, MD, MS

Intensive systolic blood pressure targets may be cost-effective across most measurement error possibilities

📢

300x250 Banner

FDA Accepts Type C Meeting for Doxorubicin-MNA in Basal Cell Carcinoma of the Skin

Tags:

Cancer Network

Weighing Relapse Risk Against Benefit in Advanced NSCLC Immunotherapy: Jonathan Thompson, MD, MS

Intensive systolic blood pressure targets may be cost-effective across most measurement error possibilities

Recent Content

COPD Biologics: Early Treatment Insights

Antihypertensive Medication Guidelines

Juvenile Arthritis Care Transition